

Wangxue Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7640273/publications.pdf>

Version: 2024-02-01

89
papers

3,686
citations

94269

37
h-index

143772

57
g-index

90
all docs

90
docs citations

90
times ranked

3515
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutrophils Play an Important Role in Host Resistance to Respiratory Infection with <i>Acinetobacter baumannii</i> in Mice. <i>Infection and Immunity</i> , 2007, 75, 5597-5608.	1.0	193
2	Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of <i>Francisella tularensis</i> : bacteriologic and histopathologic studies. <i>Microbial Pathogenesis</i> , 2003, 34, 239-248.	1.3	156
3	A Mutant of <i>Francisella tularensis</i> Strain SCHU S4 Lacking the Ability To Express a 58-Kilodalton Protein Is Attenuated for Virulence and Is an Effective Live Vaccine. <i>Infection and Immunity</i> , 2005, 73, 8345-8352.	1.0	144
4	Complete genome sequence of hypervirulent and outbreak-associated <i>Acinetobacter baumannii</i> strain LAC-4: epidemiology, resistance genetic determinants and potential virulence factors. <i>Scientific Reports</i> , 2015, 5, 8643.	1.6	132
5	Induction of mucosal immunity through systemic immunization: Phantom or reality?. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1070-1079.	1.4	131
6	A Mouse Model of <i>Acinetobacter baumannii</i> -Associated Pneumonia Using a Clinically Isolated Hypervirulent Strain. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3601-3613.	1.4	114
7	Role of Macrophages in Early Host Resistance to Respiratory <i>Acinetobacter baumannii</i> Infection. <i>PLoS ONE</i> , 2012, 7, e40019.	1.1	111
8	Tularemia in BALB/c and C57BL/6 mice vaccinated with <i>Francisella tularensis</i> LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. <i>Vaccine</i> , 2003, 21, 3690-3700.	1.7	107
9	Aerosol-, but not intradermal-immunization with the live vaccine strain of <i>Francisella tularensis</i> protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an I α 1 β 2 T cell- and interferon gamma- dependent mechanism. <i>Vaccine</i> , 2005, 23, 2477-2485.	1.7	102
10	Role of Toll-like receptors in health and diseases of gastrointestinal tract. <i>World Journal of Gastroenterology</i> , 2006, 12, 2149.	1.4	95
11	The potential of 3 β ,5 β -cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant. <i>Vaccine</i> , 2010, 28, 3080-3085.	1.7	79
12	Host Fate is Rapidly Determined by Innate Effector-Microbial Interactions During <i>Acinetobacter baumannii</i> Bacteremia. <i>Journal of Infectious Diseases</i> , 2015, 211, 1296-305.	1.9	79
13	In Vitro and In Vivo Biological Activities of Iron Chelators and Gallium Nitrate against <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5397-5400.	1.4	71
14	Reduced colonization of gastric mucosa by <i>Helicobacter pylori</i> in mice deficient in interleukin-10. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 377-383.	1.4	70
15	Distinct Roles of Reactive Nitrogen and Oxygen Species To Control Infection with the Facultative Intracellular Bacterium <i>Francisella tularensis</i> . <i>Infection and Immunity</i> , 2004, 72, 7172-7182.	1.0	69
16	Role of NADPH Phagocyte Oxidase in Host Defense against Acute Respiratory <i>Acinetobacter baumannii</i> Infection in Mice. <i>Infection and Immunity</i> , 2009, 77, 1015-1021.	1.0	69
17	Susceptibility of immunodeficient mice to aerosol and systemic infection with virulent strains of <i>Francisella tularensis</i> . <i>Microbial Pathogenesis</i> , 2004, 36, 311-318.	1.3	65
18	Contribution of Active Iron Uptake to <i>Acinetobacter baumannii</i> Pathogenicity. <i>Infection and Immunity</i> , 2019, 87, .	1.0	64

#	ARTICLE	IF	CITATIONS
19	High susceptibility to respiratory <i>Acinetobacter baumannii</i> infection in A/J mice is associated with a delay in early pulmonary recruitment of neutrophils. <i>Microbes and Infection</i> , 2009, 11, 946-955.	1.0	63
20	Differential ability of novel attenuated targeted deletion mutants of <i>Francisella tularensis</i> subspecies <i>tularensis</i> strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: Effects of host background and route of immunization. <i>Vaccine</i> , 2010, 28, 1824-1831.	1.7	60
21	Transcriptional profiling of host responses in mouse lungs following aerosol infection with type A <i>Francisella tularensis</i> . <i>Journal of Medical Microbiology</i> , 2006, 55, 263-271.	0.7	58
22	Molecular Immune Responses to Aerosol Challenge with <i>Francisella tularensis</i> in Mice Inoculated with Live Vaccine Candidates of Varying Efficacy. <i>PLoS ONE</i> , 2010, 5, e13349.	1.1	55
23	Detection of <i>Listeria monocytogenes</i> by polymerase chain reaction in intestinal mucosal biopsies from patients with inflammatory bowel disease and controls. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1145-1150.	1.4	54
24	Low dose aerosol infection of mice with virulent type A <i>Francisella tularensis</i> induces severe thymus atrophy and CD4+CD8+ thymocyte depletion. <i>Microbial Pathogenesis</i> , 2005, 39, 189-196.	1.3	54
25	Synthesis and immunostimulatory properties of the phosphorothioate analogues of cdiGMP. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5631-5634.	1.0	54
26	Chemical Synthesis and Immunological Evaluation of the Inner Core Oligosaccharide of <i>Francisella tularensis</i> . <i>Journal of the American Chemical Society</i> , 2012, 134, 14255-14262.	6.6	54
27	Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines. <i>Vaccine</i> , 2007, 25, 8622-8636.	1.7	52
28	Toll-like receptor 4 (TLR4) does not confer a resistance advantage on mice against low-dose aerosol infection with virulent type A <i>Francisella tularensis</i> . <i>Microbial Pathogenesis</i> , 2004, 37, 185-191.	1.3	50
29	3',5'-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection. <i>Biochemical and Biophysical Research Communications</i> , 2009, 387, 581-584.	1.0	50
30	M cell-targeted delivery of vaccines and therapeutics. <i>Expert Opinion on Drug Delivery</i> , 2008, 5, 693-702.	2.4	49
31	Current advances and challenges in the development of <i>Acinetobacter</i> vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2495-2500.	1.4	49
32	Oral immunization of mice with the live vaccine strain (LVS) of <i>Francisella tularensis</i> protects mice against respiratory challenge with virulent type A <i>F. tularensis</i> . <i>Vaccine</i> , 2007, 25, 3781-3791.	1.7	45
33	Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate. <i>Vaccine</i> , 2016, 34, 3371-3380.	1.7	44
34	Serum resistance, gallium nitrate tolerance and extrapulmonary dissemination are linked to heme consumption in a bacteremic strain of <i>Acinetobacter baumannii</i> . <i>International Journal of Medical Microbiology</i> , 2014, 304, 360-369.	1.5	43
35	3',5'-Cyclic diguanylic acid: a small nucleotide that makes big impacts. <i>Chemical Society Reviews</i> , 2010, 39, 2914.	18.7	42
36	Archaeosome Immunostimulatory Vaccine Delivery System. <i>Current Drug Delivery</i> , 2005, 2, 407-421.	0.8	41

#	ARTICLE	IF	CITATIONS
37	Molecular immunology of experimental primary tularemia in mice infected by respiratory or intradermal routes with type A <i>Francisella tularensis</i> . <i>Molecular Immunology</i> , 2008, 45, 2962-2969.	1.0	41
38	IL-4, IL-5 and IL-10 are not required for the control of <i>M. bovis</i> -BCG infection in mice. <i>Immunology and Cell Biology</i> , 1998, 76, 41-46.	1.0	40
39	Virulence comparison in mice of distinct isolates of type A <i>Francisella tularensis</i> . <i>Microbial Pathogenesis</i> , 2006, 40, 133-138.	1.3	39
40	Intranasal immunization protects against <i>Acinetobacter baumannii</i> -associated pneumonia in mice. <i>Vaccine</i> , 2015, 33, 260-267.	1.7	37
41	Recent advances in the development of novel mucosal adjuvants and antigen delivery systems. <i>Hum Vaccin</i> , 2010, 6, 706-714.	2.4	36
42	Host Innate Immune Responses to <i>Acinetobacter baumannii</i> Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 486.	1.8	36
43	Infection of Mice with <i>Francisella</i> as an Immunological Model. <i>Current Protocols in Immunology</i> , 2011, 93, Unit 19.14.	3.6	35
44	Toll-like receptor 4 (TLR4) plays a relatively minor role in murine defense against primary intradermal infection with <i>Francisella tularensis</i> LVS. <i>Immunology Letters</i> , 2005, 97, 151-154.	1.1	31
45	Promise and challenges in the development of COVID-19 vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2604-2608.	1.4	31
46	Role of neutrophils and NADPH phagocyte oxidase in host defense against respiratory infection with virulent <i>Francisella tularensis</i> in mice. <i>Microbes and Infection</i> , 2011, 13, 447-456.	1.0	29
47	Acute intraperitoneal infection with a hypervirulent <i>Acinetobacter baumannii</i> isolate in mice. <i>Scientific Reports</i> , 2019, 9, 6538.	1.6	28
48	Mouse Models of <i>Acinetobacter baumannii</i> Infection. <i>Current Protocols in Microbiology</i> , 2017, 46, 6G.3.1-6G.3.23.	6.5	26
49	Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant. <i>Scientific Reports</i> , 2021, 11, 21849.	1.6	26
50	Safety of Intranasally Administered Archaeal Lipid Mucosal Vaccine Adjuvant and Delivery (AMVAD) Vaccine in Mice. <i>International Journal of Toxicology</i> , 2008, 27, 329-339.	0.6	25
51	c-di-GMP protects against intranasal <i>Acinetobacter baumannii</i> infection in mice by chemokine induction and enhanced neutrophil recruitment. <i>International Immunopharmacology</i> , 2011, 11, 1378-1383.	1.7	25
52	High prevalence of <i>Mycoplasma pneumoniae</i> in intestinal mucosal biopsies from patients with inflammatory bowel disease and controls. <i>Digestive Diseases and Sciences</i> , 2001, 46, 2529-2535.	1.1	24
53	Archaeal glycolipid adjuvanted vaccines induce strong influenza-specific immune responses through direct immunization in young and aged mice or through passive maternal immunization. <i>Vaccine</i> , 2019, 37, 7108-7116.	1.7	24
54	Oral immunization of mice with a multivalent therapeutic subunit vaccine protects against <i>Helicobacter pylori</i> infection. <i>Vaccine</i> , 2020, 38, 3031-3041.	1.7	24

#	ARTICLE	IF	CITATIONS
55	Dendritic cell-based cancer immunotherapy: Potential for treatment of colorectal cancer?. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, 698-705.	1.4	23
56	Detection of Chlamydia pneumoniae by polymerase chain reaction-enzyme immunoassay in intestinal mucosal biopsies from patients with inflammatory bowel disease and controls. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 987-993.	1.4	23
57	Acinetobacter baumannii Infection Inhibits Airway Eosinophilia and Lung Pathology in a Mouse Model of Allergic Asthma. PLoS ONE, 2011, 6, e22004.	1.1	23
58	Antibiotic-Resistant <i>Acinetobacter baumannii</i> Is Susceptible to the Novel Iron-Sequestering Anti-infective DIBI <i>In Vitro</i> and in Experimental Pneumonia in Mice. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	23
59	The structure of the polysaccharide O-chain of the LPS from <i>Acinetobacter baumannii</i> strain ATCC 17961. Carbohydrate Research, 2009, 344, 474-478.	1.1	21
60	Archaeal lipid mucosal vaccine adjuvant and delivery system. Expert Review of Vaccines, 2010, 9, 431-440.	2.0	21
61	Safety and biodistribution of sulfated archaeal glycolipid archaeosomes as vaccine adjuvants. Human Vaccines and Immunotherapeutics, 2018, 14, 1746-1759.	1.4	21
62	A Slam-dependent hemophore contributes to heme acquisition in the bacterial pathogen <i>Acinetobacter baumannii</i> . Nature Communications, 2021, 12, 6270.	5.8	20
63	Intranasal Immunization with an Archaeal Lipid Mucosal Vaccine Adjuvant and Delivery Formulation Protects against a Respiratory Pathogen Challenge. PLoS ONE, 2010, 5, e15574.	1.1	17
64	Dysregulation of Ephrin receptor and PPAR signaling pathways in neural progenitor cells infected by Zika virus. Emerging Microbes and Infections, 2020, 9, 2046-2060.	3.0	16
65	Structural Characterization of Archaeal Lipid Mucosal Vaccine Adjuvant and Delivery (AMVAD) Formulations Prepared by Different Protocols and Their Efficacy Upon Intranasal Immunization of Mice. Journal of Liposome Research, 2008, 18, 127-143.	1.5	14
66	Pentabody-mediated antigen delivery induces antigen-specific mucosal immune response. Molecular Immunology, 2009, 46, 1718-1726.	1.0	14
67	The Promise and Challenges of Cyclic Dinucleotides as Molecular Adjuvants for Vaccine Development. Vaccines, 2021, 9, 917.	2.1	13
68	Parenteral immunization with a cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) adjuvanted <i>Helicobacter pylori</i> vaccine induces protective immunity against <i>H. pylori</i> infection in mice. Human Vaccines and Immunotherapeutics, 2020, 16, 2849-2854.	1.4	12
69	Characterization of Extremely Drug-Resistant and Hypervirulent <i>Acinetobacter baumannii</i> ABO30. Antibiotics, 2020, 9, 328.	1.5	11
70	Potential Mechanisms of Mucin-Enhanced <i>Acinetobacter baumannii</i> Virulence in the Mouse Model of Intraperitoneal Infection. Infection and Immunity, 2019, 87, .	1.0	10
71	Iron-withdrawing anti-infectives for new host-directed therapies based on iron dependence, the Achilles' heel of antibiotic-resistant microbes. Environmental Chemistry Letters, 2021, 19, 2789-2808.	8.3	9
72	Profiling of Cytokine and Chemokine Responses Using Multiplex Bead Array Technology. Methods in Molecular Biology, 2019, 2024, 79-94.	0.4	9

#	ARTICLE	IF	CITATIONS
73	Inhibition of mitogenâ€nduced murine lymphocyte proliferation by <i>Helicobacter pylori</i> cellâ€free extract. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1000-1006.	1.4	8
74	Will the mRNA vaccine platform be the panacea for the development of vaccines against antimicrobial resistant (AMR) pathogens?. <i>Expert Review of Vaccines</i> , 2022, 21, 155-157.	2.0	8
75	Where are we and how far is there to go in the development of an <i>Acinetobacter</i> vaccine?. <i>Expert Review of Vaccines</i> , 2021, 20, 281-295.	2.0	7
76	DNA Based Vaccine Expressing SARS-CoV-2 Spike-CD40L Fusion Protein Confers Protection Against Challenge in a Syrian Hamster Model. <i>Frontiers in Immunology</i> , 2021, 12, 785349.	2.2	7
77	Host resistance to intranasal <i>Acinetobacter baumannii</i> reinfection in mice. <i>Pathogens and Disease</i> , 2016, 74, ftw048.	0.8	5
78	Identification of an immunogenic 18-kDa protein of <i>Helicobacter pylori</i> by alkaline phosphatase gene fusions. <i>Journal of Medical Microbiology</i> , 2000, 49, 643-650.	0.7	4
79	Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages. <i>IScience</i> , 2021, 24, 103328.	1.9	4
80	Lymphotoxin- α Plays Only a Minor Role in Host Resistance to Respiratory Infection with Virulent Type A <i>Francisella tularensis</i> in Mice. <i>Mediators of Inflammation</i> , 2008, 2008, 1-6.	1.4	3
81	2-Fluoro-c-di-GMP as an oral vaccine adjuvant. <i>RSC Advances</i> , 2019, 9, 41481-41489.	1.7	3
82	Hostâ€pathogen interactions in <i>Acinetobacter baumannii</i> infection: recent advances and future challenges. <i>Future Microbiology</i> , 2020, 15, 841-845.	1.0	3
83	Exploiting the Achillesâ€™ Heel of Iron Dependence in Antibiotic Resistant Bacteria with New Antimicrobial Iron Withdrawal Agents. <i>Sustainable Agriculture Reviews</i> , 2021, , 251-311.	0.6	3
84	Novel anti- <i>Helicobacter pylori</i> agents. <i>Expert Opinion on Therapeutic Patents</i> , 2000, 10, 1221-1232.	2.4	2
85	Vaccines and therapeutic agents for tularemia. <i>Expert Opinion on Therapeutic Patents</i> , 2007, 17, 267-275.	2.4	2
86	Non-antibiotic strategies for the prevention/treatment of <i>Clostridium difficile</i> infection. <i>Expert Opinion on Therapeutic Patents</i> , 2008, 18, 1395-1403.	2.4	1
87	Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	1
88	Novel cancer vaccines: an update. <i>Expert Opinion on Therapeutic Patents</i> , 2003, 13, 1787-1799.	2.4	0
89	Therapeutic potential of microbes and microbial products in the management of human allergic asthma. <i>Expert Opinion on Therapeutic Patents</i> , 2005, 15, 789-799.	2.4	0